MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: A comprehensive meta-analysis based on a Cochrane Systematic Review

Sebastian Brandner , Alexandra McAleenan, Claire Kelly, Francesca Spiga, Hung-Yuan Cheng, Sarah Dawson, Lena Schmidt, Claire Faulkner, Christopher Wragg , Sarah Jefferies, Julian P T Higgins, Kathreena M Kurian*

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

2 Citations (Scopus)
16 Downloads (Pure)

Abstract

BACKGROUND
The DNA repair protein O6 methylguanine-DNA methyltransferase (MGMT) causes resistance of tumour cells to alkylating agents. It is a predictive biomarker in high grade gliomas treated with temozolomide, however there is no consensus on which test method, methylation sites, and cut-off values to use.

METHODS
We performed a Cochrane Review to examine studies using different techniques to measure MGMT and predict survival in glioblastoma patients treated with temozolomide. Eligible longitudinal studies included adults with glioblastoma treated with temozolomide with or without radiotherapy, or surgery; where MGMT status was determined in tumour tissue, and assessed by one or more technique; and where overall survival was an outcome parameter, with sufficient information to estimate hazard ratios. Two or more methods were compared in 32 independent cohorts with 3474 patients.

RESULTS
Methylation-specific PCR (MSP) and pyrosequencing (PSQ) techniques were more prognostic than immunohistochemistry for MGMT protein, and PSQ is a slightly better predictor than MSP.

CONCLUSIONS
We cannot draw strong conclusions about use of frozen tissue versus formalin-fixed paraffin embedded in MSP and PSQ. Also, our meta-analysis does not provide strong evidence about the best CpG sites or threshold. MSP has been studied mainly for CpG sites 76-80 and 84-87 and Pyrosequencing at CpG sites ranging from 72 to 95. A cut-off threshold of 9% for CpG sites 74-78 performed better than higher thresholds of 28% or 29% in two of three good-quality studies. 190 studies were identified presenting hazard ratios from survival analysis in patients in which MGMT methylation was measured by one technique only.
Original languageEnglish
Article numbernoab105
Pages (from-to)1457-1469
Number of pages13
JournalNeuro-oncology
Volume23
Issue number9
Early online date30 Apr 2021
DOIs
Publication statusPublished - 1 Sep 2021

Bibliographical note

Funding Information:
This project was supported in part by the National Institute for Health Research (NIHR), via Cochrane Programme Grant funding (16/144) to the Cochrane Gynaecological, Neuro-oncology and Orphan Cancers Group. A.M., F.S., and J.P.T.H. were supported in part by Cancer Research United Kingdom (grant number C18281/ A19169). S.B. was partly supported by the NIHR Biomedical Research Centre to University College London Hospitals.

Publisher Copyright:
© 2021 The Author(s) 2021.

Structured keywords

  • ICEP

Keywords

  • MGMT promoter methylation
  • glioblastoma
  • temozolomide
  • meta-analysis
  • prognostic biomarker

Fingerprint

Dive into the research topics of 'MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: A comprehensive meta-analysis based on a Cochrane Systematic Review'. Together they form a unique fingerprint.

Cite this